Share on StockTwits

DexCom (NASDAQ:DXCM) VP Richard Doubleday unloaded 4,000 shares of DexCom stock on the open market in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $38.16, for a total transaction of $152,640.00. Following the transaction, the vice president now directly owns 126,136 shares in the company, valued at approximately $4,813,350. The transaction was disclosed in a filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, June 27th. They now have a $42.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday, June 17th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $39.60.

DexCom (NASDAQ:DXCM) traded down 0.18% on Thursday, hitting $38.43. 557,031 shares of the company’s stock traded hands. DexCom has a 1-year low of $21.76 and a 1-year high of $49.83. The stock has a 50-day moving average of $38.03 and a 200-day moving average of $38.27. The company’s market cap is $2.879 billion.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. The company’s revenue for the quarter was up 59.1% on a year-over-year basis. Analysts expect that DexCom will post $-0.33 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.